Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA

Am J Hematol. 2011 Feb;86(2):237-8. doi: 10.1002/ajh.21937.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Azacitidine / administration & dosage
  • Cohort Studies
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Leukemia, Myeloid, Acute / blood*
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukocytes, Mononuclear / metabolism*
  • MicroRNAs / blood*
  • Myelodysplastic Syndromes / blood
  • Myelodysplastic Syndromes / drug therapy
  • Treatment Outcome
  • Tretinoin
  • Valproic Acid / administration & dosage

Substances

  • Antineoplastic Agents
  • MIRN29a microRNA, human
  • MicroRNAs
  • Tretinoin
  • Valproic Acid
  • Azacitidine